Versartis Inc. (NASDAQ:VSAR) shares traded down 3.3% on Thursday . The company traded as low as $9.85 and last traded at $9.98, with a volume of 58,640 shares trading hands. The stock had previously closed at $10.32.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Versartis from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Versartis in a research note on Tuesday, May 10th. Morgan Stanley reaffirmed a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. Finally, Northland Securities assumed coverage on shares of Versartis in a research note on Thursday, April 7th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $17.20.

The company’s 50 day moving average price is $10.25 and its 200-day moving average price is $9.38. The firm’s market capitalization is $295.46 million.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.